IDEC-C2B8 anti-lymphoma antibody targeting the CD20 antigen on mature B cells and on B cell tumors: Began a single-arm, single-agent Phase III trial in the U.S.

Genentech Inc. (GNE), South San Francisco IDEC Pharmaceuticals Corp. (IDPH), San Diego Product: IDEC-C2B8 anti-lymphoma antibody targeting the CD20 antigen on mature B cells and on B cell tumors In...